Trial Profile
A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2015
Price :
$35
*
At a glance
- Drugs Polyclonal antibody stimulator (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Cancer Advances
- 12 May 2015 New trial record